Skip to main content
OpenTrials
Completed

NCT Number: NCT05737979

Modified Rekovelle and Menopur Combination Protocol to Avoid Monitoring Before Day 10 of Stimulation

Follitropin delta (Rekovelle) algorithm established by Ferring provides personalized gonadotrophin doses based on each patient's weight and AMH. As a result, risks of stimulation failure or ovarian hyperstimulation syndrome (OHSS) during an in vitro fertilization (IVF) cycle are minimized.

As a standard practice for OHSS prevention at clinique ovo, women undergoing IVF will have a scheduled ultrasound and blood test on the sixth day of their stimulation treatment. However, with the determination of the Rekovelle and Menopur algorithm, the risks of OHSS before the tenth day have been considerably minimized.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Infertility Genital Diseases IVF Urogenital Diseases

Age range

18 year and older

Sex eligibility

Female

Study type

Observational

Primary location

Clinique Ovo

Montreal, Quebec, H4P 2S4, Canada

About this study

The purpose of this study is to evaluate the necessity of programming an ultrasound and blood test prior to the tenth day of ovarian stimulation when women are on personalized doses of Rekovelle and Menopur duting an antagonist IVF cycle. Based on the results of the analysis, we will assess the economic impact that programming an ultrasound and blood test at day 10 might have.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Women of 18 years of age or older having provided consent to chart access for scientific publication in the IVF consent form
  • Antagonist IVF cycle using combination of Rekovelle and Menopur for stimulation according to the modified protocol employed at clinique ovo without deviation
  • Presence of both ovaries

Exclusion criteria

  • Second cycle of Duo-Stim IVF

Treatment and study plan

Study chart review

Other

Evaluation of the IVF cycle using the prescribed medication

Primary outcomes

  1. Identify the population where a simplified IVF monitoring is conceivable

    Time frame: Up to 3 weeks

    Rate of Rekovelle and / or Menopur dose modification before day 10 ultrasound

Sponsors and collaborators

Lead sponsor

Clinique Ovo

Industry

Registry information

Important dates

Study start
2023
Primary completion
2023
Study completion
2024
First posted
Feb 21, 2023
Registry last updated
Feb 20, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.